ArticleActa parasitologica2026
Sero-evidence of Latent Toxoplasma Gondii Infection in Cancer Patients Before and After Chemotherapy, Northern Iran.
Article in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToxoplasmosis, caused by Toxoplasma gondii, affects a significant proportion of the global population. While typically asymptomatic in healthy individuals due to effective immune responses, immunocompromised individuals, such as cancer patients undergoing chemotherapy, are at risk of developing acute toxoplasmosis due to the reactivation of latent infection. This study aims to investigate the seroprevalence of latent T. gondii infection among cancer patients who were registered with the Iranian National Registry Center for Toxoplasmosis (INRCT), before and after chemotherapy, and to determine the relationship between chemotherapy and IgG antibody responses. PATIENTS AND
methodsThis cross-sectional study investigated the seroprevalence of T. gondii infection and its relationship with chemotherapy in 107 cancer patients with solid organ tumors. Participants were recruited from oncology centers in Sari, northern Iran, between 2023 and 2024 and were assessed for anti-T. gondii IgG and IgM antibodies using ELISA before and three weeks after chemotherapy initiation.
resultsAt baseline, 80.4% of patients were IgG positive, indicating prior T. gondii exposure. Three weeks post-chemotherapy, 28.92% showed a significant increase in IgG titers. While age was significantly associated with Toxoplasma infection at baseline (P < 0.05), no significant associations were found between demographic or clinical characteristics and IgG seropositivity or titer changes post-chemotherapy. Breast cancer patients exhibited the highest prevalence of Toxoplasma IgG.
conclusionsThese findings suggest a high prevalence of latent toxoplasmosis in cancer patients, with chemotherapy potentially influencing IgG titers in a subset of individuals, independent of other factors examined. Further research is needed to elucidate the underlying mechanisms and clinical implications of these observations.
Indexed as
Identifiers
41661400What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.